title: Biologics and Pediatric Generalized Pustular Psoriasis: An Emerging Therapeutic Trend.
abstract: Generalized pustular psoriasis (GPP) is a rare form of childhood psoriasis, often requiring systemic therapy, which is challenging as there is a paucity of randomized controlled trials and standardized guidelines. Biologic agents have been used in adults and in pediatric plaque psoriasis, but evidence regarding their efficacy in pediatric GPP has slowly become available. The objective of this study is to summarize and compare the efficacy and safety of biologic agents, such as etanercept, infliximab, and adalimumab, in the treatment of pediatric GPP. A PubMed literature review was conducted and 12 studies met the inclusion criteria for analysis. After reviewing the efficacy of these drugs in pediatric GPP patients and their safety in the use of other pediatric conditions, etanercept was identified as a possible first-line biologic agent for pediatric psoriasis, including GPP, followed by infliximab and adalimumab. In conclusion, several case reports have documented the successful use of biologic agents in refractory cases of pediatric GPP, but clinical trials are needed to gain a better understanding of the efficacy and side effect profile in this population.
authors.affiliation: College of Medicine, University of Central Florida College of Medicine.
authors.forename: Sami K
authors.initials: SK
authors.lastname: Saikaly
authors.affiliation: College of Medicine, University of Central Florida College of Medicine.
authors.forename: Monica
authors.initials: M
authors.lastname: Mattes
keywords: adalimumab; biologics; etanercept; generalized pustular psoriasis; gpp; infliximab; pediatric; psoriasis